Status:
COMPLETED
The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
Lead Sponsor:
BeiGene
Conditions:
Healthy
Male
Eligibility:
MALE
18-65 years
Phase:
PHASE1
Brief Summary
The primary objective of this study was to determine the effect of the moderate cytochrome P450 3A (CYP3A) inducer rifabutin on the pharmacokinetics (PK) of zanubrutinib in healthy males.
Eligibility Criteria
Inclusion
- Key
- Males of any race, between 18 and 65 years of age, inclusive.
- Male participants in good health as determined by past medical history, physical examination, vital signs, ECG and laboratory tests at screening
- Must have a body mass index (BMI) between 18 and 32 kg/m\^2
- Key
Exclusion
- Participants with a clinically relevant history or presence of any clinically significant disease
- History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair will be allowed)
- History of drug or alcohol abuse within 1 year prior to check-in
- Use or intended use of any nonprescription medications/products including vitamins, minerals, herbal/plant-derived preparations within 7 days prior to check-in
- A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result and/or a positive human immunodeficiency virus (HIV) at screening
- Use of tobacco- or nicotine-containing products within 3 months prior to check-in
- Use or intended use of any prescription medications/products within 14 days prior to check-in
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
July 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2020
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT04470908
Start Date
July 29 2020
End Date
November 10 2020
Last Update
October 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Unit
Daytona Beach, Florida, United States, 32117